ULTRAGENYX PHARMACEUTICAL INC. Conversion of Stock, Amount Converted
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Conversion of Stock, Amount Converted of $129.36 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ConversionOfStockAmountConverted1 · last filed 2017-02-17
- ULTRAGENYX PHARMACEUTICAL INC. conversion of stock, amount converted for the quarter ending 2014-12-31 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. conversion of stock, amount converted for the quarter ending 2014-09-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. conversion of stock, amount converted for the quarter ending 2014-06-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. conversion of stock, amount converted for the quarter ending 2014-03-31 was $129.36M.
- ULTRAGENYX PHARMACEUTICAL INC. conversion of stock, amount converted for fiscal 2014 was $129.36M.
| Period end | Conversion of Stock, Amount Converted 3 month | Conversion of Stock, Amount Converted 6 month | Conversion of Stock, Amount Converted 9 month | Conversion of Stock, Amount Converted 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 derived: sum of 3 quarters · filed 2017-02-17 | $129.36M 10-K · filed 2017-02-17 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $129.36M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $129.36M 10-Q · filed 2015-08-14 | ||
| 2014-03-31 | $129.36M 10-Q · filed 2015-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |